Compare stocks

CCM vs SCNX

Concord Medical Services Holding Limited and Scienture Holdings, Inc. Common Stock

Compare the businesses

Concord Medical Services Holding Limited

Concord Medical Services Holdings Limited, through its subsidiaries, operates a network of radiotherapy and diagnostic imaging centers in the People's Republic of China. It operates in two segments, Network and Hospital. The company's services include linear accelerators and external beam radiotherapy, proton therapy system, gamma knife radiosurgery, and diagnostic imaging services. Its other treatments and diagnostic services comprise positron emission tomography-computed tomography and magnetic resonance imaging scanners. In addition, the company provides clinical support services, such as developing treatment protocols for doctors, and organizing joint diagnosis between doctors in its network and clinical research, as well as helps to recruit and determine the compensation of doctors and other medical personnel. Further, it offers radiotherapy and diagnostic equipment leasing, management services, and premium cancer and proton treatment services to hospitals, as well as teleconsultation and medical information technology services; and sells medical equipment. Additionally, the company operates specialty cancer hospitals, which offers radiation, imaging, test laboratory, inpatient, and nursing services. Concord Medical Services Holdings Limited was founded in 1997 and is headquartered in Beijing, China.

Open CCM dashboard ↗

Scienture Holdings, Inc. Common Stock

Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company operates through Integra and Scienture segments. The Integra segment engages in the wholesale and sale of licensed pharmaceutical brand, generic, and non-drug products. The Scienture segment researches and develops branded pharmaceutical products. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy; and SCN-104, a multi-dose dihydroergotamine mesylate (DHE) injection pen. It also develops SCN-106, which is a thrombolytic agent that binds to fibrin in clots and converts entrapped plasminogen to plasmin; and SCN-107, a long-acting injection suspension formulation of a non-opioid analgesic for postsurgical local and regional analgesia. Scienture Holdings, Inc. is based in Tampa, Florida.

Open SCNX dashboard ↗

Sign in to keep comparing stocks

You've viewed 3 distinct stock or comparison pages today. Sign in for 10 views per day.

3 of 3 daily views used. Your allowance resets at midnight Eastern time. Refreshes and chart changes do not use another view.

New to NexusTrade? Create a free account.

Choose another comparison ↗